Showing results (161-170 of 239) with videos related to

Sort By:
Pageof 24
Breast (Edinburgh, Scotland)|March 28, 2016
Second international consensus guidelines for breast cancer in young women (BCY2)Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, et al.
NPJ Precision Oncology|April 1, 2025
Zebrafish Avatar testing preclinical study predicts chemotherapy response in breast cancerRaquel V Mendes, Joana M Ribeiro, Helena Gouveia, et al.
Breast (Edinburgh, Scotland)|February 6, 2021
Breast cancer surgery with augmented realityPedro F Gouveia, Joana Costa, Pedro Morgado, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2020
Management of Male Breast Cancer: ASCO GuidelineMichael J Hassett, Mark R Somerfield, Elisha R Baker, et al.
CA: a Cancer Journal for Clinicians|February 19, 2020
Enhancing global access to cancer medicinesJavier Cortes, Jose Manuel Perez-García, Antonio Llombart-Cussac, et al.
Breast (Edinburgh, Scotland)|August 20, 2017
ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3)Shani Paluch-Shimon, Olivia Pagani, Ann H Partridge, et al.
JCO Global Oncology|February 1, 2024
Advanced Breast Cancer Guidelines in Latin America: Assessment, Adaptation, and Implementation of Fifth Advanced Breast Cancer Consensus GuidelinesFernando Valencia, Henry L Gómez, Silvia P Neciosup, et al.
Journal of the National Cancer Institute|June 24, 2024
Neoadjuvant pembrolizumab plus chemotherapy/adjuvant pembrolizumab for early-stage triple-negative breast cancer: quality-of-life results from the randomized KEYNOTE-522 studyRebecca Dent, Javier Cortés, Lajos Pusztai, et al.
Lancet (London, England)|March 8, 2011
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyJavier Cortes, Joyce O'Shaughnessy, David Loesch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancerStephen Chan, Max E Scheulen, Stephen Johnston, et al.
Pageof 24